ArticleRisk management and healthcare policy2026
Public Willingness to Pay for Alzheimer's Preventive Medication in Iran: A Contingent Valuation Study.
Article in Risk management and healthcare policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alzheimer's disease is associated with substantial health and economic burdens worldwide. As the prevalence of the disease continues to increase, understanding public willingness to pay (WTP) for preventive interventions is important for healthcare planning and policy development. This study estimated WTP for a hypothetical Alzheimer's preventive drug and identified factors associated with WTP among adults in Iran. Methods: A descriptive-analytical cross-sectional study was conducted in 2025 among 495 adults aged 18-70 years (mean age: 36.05 ± 10.09 years) in Kermanshah, Iran, who were selected using multistage cluster sampling. WTP was assessed using the contingent valuation method (CVM) with a double-bounded dichotomous choice (DBDC) format. Responses were analyzed using a maximum-likelihood estimation model. Results: Seventy-two percent of participants expressed WTP for an Alzheimer's preventive drug. The estimated monthly mean WTP was 5,150,000 Iranian Rials (IRR) (approximately USD 5.1 at the time of the study). Higher WTP was significantly associated with gender, insurance coverage, preventive attitudes, perceived risk of Alzheimer's disease, and risk-taking behavior. Age, marital status, and educational attainment were not significantly associated with WTP. Conclusion: Participants placed considerable value on potential Alzheimer's disease prevention. The findings suggest that insurance coverage, public awareness initiatives, and consideration of individual risk perceptions may be important factors in the design and implementation of future Alzheimer's prevention programs. These findings should be interpreted in light of the cross-sectional design of the study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.